In an updated safety communication dated October 25, the FDA states: “The U.S. Food and Drug Administration is alerting consumers, health care providers and health care facilities not to use BioZorb Markers and BioZorb LP Markers by Hologic (HOLX) Inc. On October 25, 2024, Hologic announcedExternal Link Disclaimer a voluntary recall for removal of all lots of unused BioZorb Markers. The recall is due to reports of serious adverse events occurring in patients who had the devices implanted in breast tissue. The FDA is issuing this communication to help ensure you are aware of the manufacturer’s most recent recall notice and the recommended actions.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on HOLX:
- Hologic price target raised to $90 from $85 at Mizuho
- Meta, Alphabet initiated: Wall Street’s top analyst calls
- Hologic price target raised to $82 from $78 at Evercore ISI
- Hologic downgraded to Neutral from Buy at Citi
- Hologic announces $1.5B share repurchase program
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
